Vetenskapliga artiklar
Här kan du beställa de viktigaste artiklarna kring våra senaste läkemedel
Vänligen fyll i antal exemplar av de tryckta artiklarna du önskar och klicka på "Add to cart". När du gjort det, klicka på "Proceed" längst ner på sidan för att komma till nästa steg i beställningen.
| Items | ||
| Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier S Int J Geriatr Psychiatry 2005; 20: 459–464 | ||
| A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Löthgren M et al. Primary Care Psychiatri 2004; 9(4): 153-161 | ||
| A Randomised Study Comparing Escitalopram with Venlafaxine XR in Patients in Primary Care with Major Depressive Disorder. Montgomery SA et al. Psychoneurobiology 2004;50:57–64 | ||
| Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder. Bielski RJ et al. J Clin Psychiatry 65:9, Sept 2004 | ||
| Escitalopram versus citalopram: the surprising role of the R-enantiomer. Sánchez et al. Psychopharmacology 2004;174:163-176 | ||
| Prospective, multicenter, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment in major depressive disorder. Moore et al. Int Clin Psychpharmacology 2005;20:131-137 | ||
| Efficacy and Tolerability of Escitalopram in 12- and 24-week Treatment of Social Anxiety Disorder: Randomised, Double-blind, Placebo-controlled, Fixed-dose study. Lader et al. Depression and Anxiety 2004; 19: 241-248 (vs Paroxetine) | ||
| Escitalopram in the Treatment of Social Anxiety Disorder Randomised, placebo-controlled, flexible-dosage study. Kasper et al. Br J Psych 2005; 186:222-226 | ||
| Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Allgulander et al. International Journal of Neuropsychopharmacology 2005; 9: 1-11 | ||
| A Double-blind Comparison of Escitalopram and Paroxetine in the Treatment of Generalized Anxiety Disorder. Bielski et al. Annals of Clinical Psychiatry 2005 17:65-69 | ||
| Escitalopram in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo Controlled, Flexible-Dose Study. Davidson et al. Depression and Anxiety 2004; 19:234-240 | ||
| The place of memantine in the treatment of Alzheimer's disease : a mumber needed to treat analysis. Livingston G., Katona C. Int J Geriatr Psychiatry 2004;19: 919-925 | ||
| Resource Utilisation and cost analysis of memenatine in patients with moderat to severe Alzheimer's disease. Wimo A et al. Pharmacoeconomics 2003; 21: 327-340 | ||
| Memantine. A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer’s Disease. Plosker G L & Lyseng-Williamson KA. Pharmacoeconomics 2005; 23 (2): 193-206 | ||
| Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data Parsons C G, Danysz W, Quack G. . Neuropharmacology 1999; 38: 735–767 | ||
| Memantine treatment in patient with moderate to severe Alzheimers disease already receiving Donepezil Tariot P N et al. JAMA 2004; 291: 317-324 | ||
| Memantine in severe dementia : Results of the M-BEST study (Benefits and Efficacy in severly demented patients during treatment with memantine. Winblad B. & Poritis N. Int. J. Geriat. Psychiatry 1999; 14: 135-146 | ||
| Memantine in Moderate-to-Severe Alzheimer’s Disease Riesberg B et al. N Engl J Med 2003;348:1333-1341. | ||
Go to top
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Ottiliavej 9
DK-2500 Copenhagen Valby
Tel +45 36 30 13 11
Fax +45 36 30 19 40
Fax +45 36 30 19 40
The specialist in psychiatry and pioneer in neurology
Disclaimer & Privacy statement
Disclaimer & Privacy statement